Listen to Gynecologic Oncology

Editor's Choice:  Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201Editorial: MEK-Ing progress in low-grade serous ovarian cancerHosted by: Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, United States of AmericaFeaturing: Rachel N. Grisham MD, Memorial Sloan Kettering Cancer Center, New York, United States of AmericaDavid M. Gershenson, MD, The University of Texas MD Anderson Cancer Center, Houston, United States of AmericaCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Pregnancies in gynecologic oncologists: An assessment of pregnancy policies and complications within a surgical subspecialtyEditorial: Pregnancy complications in gynecologic oncologists – A call to action to do betterHosted by: Paola Gehrig, MDUniversity of Virginia , Charlottesville,  United States of AmericaFeaturing: Kelsey Goon, MDUniversity of Chicago, United States of AmericaKathryn A. Mills, MDUniversity of Chicago, United States of AmericaChristine S. Walsh, MDUniversity of Colorado School of Medicine, United States of AmericaBrooke Sanders, MDWashington University School of Medicine, United States of AmericaCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  FIGO 2023 staging may result in overtreatment of early-stage endometrial cancerEditorial: A path to precision in endometrial cancer management: Moving past FIGO 2023Hosted by: David Gaffney, MD, PhDThe University of Utah, Salt Lake City, Utah, United States of AmericaFeaturing: Allison Roy, MDSUNY Upstate Medical University, Syracuse, NY, United States of AmericaJessica N. McAlpineUniversity of British Columbia,  Vancouver, BC, CanadaDavid MutchWashington University School of Medicine, St Louis, MO, United States of AmericaCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 updateEditorial: The evolving landscape of personalized perioperative care: A commentary on the 2026 ERAS® Gynecologic oncology guidelinesHosted by: Sean C. Dowdy, MD; Division of Gynecologic Oncology, Mayo Clinic College of Medicine, Rochester, MN, USAFeaturing: Gregg Nelson, MD, PhD; Department of Obstetrics & Gynecology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, CanadaRichard D. Urman, MD; Department of Anesthesiology, The Ohio State University Wexner Medical Center and College of Medicine, Columbus, OH, USAOlle Ljungqvist, MD, PhD; Department of Molecular Medicine & Surgery, Karolinska Institutet, Stockholm, SwedenCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trialEditorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancerHosted by: Amanda Nickles Fader, MD; Johns Hopkins Medicine Baltimore, MD, USAFeaturing: Kathleen Moore, MD; Gynecologic Cancer Clinic, Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma City, OK, USARamez N Eskander, MD;  Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, UC San Diego, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleedingEditorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practiceHosted by: Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USAFeaturing: Jamie N. Bakkum-Gamez, MD; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USAJohn B. Kisiel, MD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USAJoy M. Davis MD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice reviewModerator:Ursula A. Matulonis, MD; Dana-Farber Cancer InstituteSpeakers:Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone HealthRóisín E. O’Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical CollegeYvette Drew, MBBS, PhD; BC Cancer Centre Vancouver and University of British ColumbiaChristina Washington, MD; Stephenson Cancer Center, University of OklahomaUrsula A. Matulonis, MD, is joined by Bhavana Pothuri, MD, Róisín O’Cearbhaill, MD, Yvette Drew, MBBS, PhD, and Christina Washington, MD, to discuss recent updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors (PARPi) in ovarian cancer. Based on the recent Society of Gynecologic Oncology clinical practice review published in Gynecologic Oncology, the speakers review the evolving role of PARP inhibitors and the clinical implications of updated regulatory approvals.The panel explores current evidence supporting PARP inhibitor use in ovarian cancer, including considerations for patient selection, biomarker testing, maintenance therapy, and safety considerations. The speakers also discuss how recent changes in FDA indications may affect clinical decision-making and treatment sequencing in practice.This podcast highlights practical clinical pearls to help guide practitioners in the appropriate integration of PARP inhibitors into the management of ovarian cancer patients.This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancerEditorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selectionHosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta CanadaFeaturing: Surabhi Tewari, MD, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USAAlexander Melamed, MD MPH, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USAJose Alejandro Rauh-Hain, MD MPH, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statementHosted by:Jose Alejandro Rauh-Hain, MD MPHDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAFeaturing:Charles A. Powell, MD, MBADivision of Pulmonary, Critical Care and Sleep Medicine, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trialEditorial: Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup Canadian Cancer Trials Group Cx.5/SHAPE trialHosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta CanadaFeaturing: Janice S. Kwon  MD, MPH, FRCSC, University of British Columbia, Vancouver, Canada and  R. Wendel Naumann, MD Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28203, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net